Recomendaciones de la Sociedad Española de Farmacia Hospitalaria, la Sociedad Española de Enfermería Oncológica y la Sociedad Española de Oncología Médica para el manejo seguro de la medicación antineoplásica del paciente con cáncer

María José Otero; Ruth Vera; Cristina González-Pérez; Francisco Ayala de la Peña; Ángeles Peñuelas; Nuria Quer

doi:10.7399/fh.11132

Recomendaciones de la Sociedad Española de Farmacia Hospitalaria, la Sociedad Española de Enfermería Oncológica y la Sociedad Española de Oncología Médica para el manejo seguro de la medicación antineoplásica del paciente con cáncer

María José Otero, Ruth Vera, Cristina González-Pérez, Francisco Ayala de la Peña, Ángeles Peñuelas, Nuria Quer

Resumen

Objetivo: Definir unas recomendaciones que permitan el manejo seguro de la medicación antineoplásica, minimizar los errores de medicación y mejorar la seguridad de los pacientes oncológicos tratados.

Método: A partir de una revisión de la bibliografía, así como de la consulta de páginas web de varias agencias y organismos sanitarios, un comité de expertos de la Sociedad Española de Farmacia Hospitalaria y la Sociedad Española de Oncología Médica han definido una serie de prácticas seguras para todas las etapas de la provisión del tratamiento antineoplásico al paciente. La Sociedad Española de Enfermería Oncológica revisó y respaldó la lista final.

Resultados: Se han definido 68 recomendaciones estructuradas en 5 secciones. Se incluyen aspectos relacionados con la formación de los profesionales sanitarios; los recursos tecnológicos necesarios; la planificación del tratamiento; la información al paciente y a sus familiares; los procesos de prescripción, preparación, dispensación y administración del tratamiento antineoplásico (por vía oral, parenteral o intratecal), así como la evaluación de la adherencia del paciente y la toxicidad del tratamiento.

Conclusiones: El establecimiento de medidas concretas destinadas a prevenir los errores de medicación en los centros sanitarios es esencial para garantizar la seguridad de los pacientes oncológicos tratados con medicación antineoplásica.

Palabras clave

Agentes antineoplásicos; Errores de medicación; Prevención y control; Seguridad del paciente; Sistema seguro de organización y administración

Texto completo:

PDF (English)

Referencias

Schwappach DL, Wernli M. Medication errors in chemotherapy: Incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care (Engl). 2010;19(3):285-92. DOI:10.1111/j.1365-2354.2009.01127.x

Marliot G, Le Rhun E, Sakji I, Bonneterre J, Cazin JL. Securing the circuit of intrathecally administered cancer drugs: Example of a collective approach. J Oncol Pharm Pract. 2011;17(3):252-9. DOI:10.1177/1078155210372550

Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: Strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer. 2009;124(3):722-8. DOI:10.1002/ijc.23991

Jaehde U, Liekweg A, Simons S, Westfeld M. Minimising treatment- associated risks in systemic cancer therapy. Pharm World Sci. 2008;30(2):161-8. DOI:10.1007/s11096-007-9157-4

Easty AC, Coakley N, Cheng R, Cividino M, Savage P, Tozer R, et al. Safe handling of cytotoxics: Guidelines recommendations. Curr Oncol. 2015;22(1):e27-37. DOI:10.3747/co.21.2151

Gramage Caro T, Palomar Fernández C, Pueyo López C, Sánchez Cuervo M, Gómez de Salazar López de Silanes ME, Bermejo Vicedo T. Validating a classification scheme for medication errors to be used in chemotherapy. Farm Hosp. 2011;35(4):197-203. DOI:10.1016/j.farma.2010.04.006

Saad A, Der-Nigoghossian CA, Njeim R, Sakr R, Salameh P, Massoud M. Prescription errors with chemotherapy: Quality improvement through standardized order templates. Asian Pac J Cancer Prev. 2016;17(4):2329- 36.

Trudeau M, Green E, Cosby R, Charbonneau F, Easty T, Ko Y, et al. Key components of intravenous chemotherapy labeling: A systematic review and practice guideline. J Oncol Pharm Pract. 2011;17(4):409-24. DOI:10.1177/1078155210385160

Ng T, Badry N, de Lemos ML. Rationalizing the use of auxiliary label for oral oncology drugs. J Oncol Pharm Pract. 2017;23(5):338-43. DOI:10.1177/1078155216650986

Trudeau M, Green E, Cosby R, Charbonneau F, Easty T, Ko Y, et al. Patient Safety Issues: Key Components of Chemotherapy Labelling 2009 [cited 2018 April 11]. Available at: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/su mmary/pebc12-11s.pdf.

Dobish R, Shultz J, Neilson S, Raven A, Chambers CR. Worksheets with embedded checklists support IV chemotherapy safer practice. J Oncol Pharm Pract. 2016;22(1):142-50. DOI:10.1177/1078155214556009

Gandhi S, Tyono I, Pasetka M, Trudeau M. Evaluating an oncology systemic therapy computerized physician order entry system using international guidelines. J Oncol Pract. 2014;10(2):e14-25. DOI:10.1200/JOP.2013.000914

Kukreti V, Cosby R, Cheung A, Lankshear S, ST Computerized Prescriber Order Entry Guideline Development Group. Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful use. Curr Oncol. 2014;21(4):e604-12. DOI:10.3747/co.21.1990

Ortiz-Martin B, Pena-Cabia S. Degree of technological implementation in intravenous chemotherapy management in hospitals of the Autonomous Community of Madrid. Farm Hosp. 2017;41(4):488-96. DOI:10.7399/fh.2017.41.4.10729

Shulman LN, Miller RS, Ambinder EP, Yu PP, Cox JV. Principles of safe practice using an oncology EHR system for chemotherapy ordering, preparation, and administration, Part 2 of 2. J Oncol Pract. 2008;4(5):254-7. DOI:10.1200/JOP.0857501

Kullberg A, Larsen J, Sharp L. ‘Why is there another person’s name on my infusion bag?’ Patient safety in chemotherapy care - a review of the literature. Eur J Oncol Nurs. 2013;17(2):228-35. DOI:10.1016/j.ejon.2012.07.005

Bubalo J, Warden BA, Wiegel JJ, Nishida T, Handel E, Svoboda LM, et al. Does applying technology throughout the medication use process improve patient safety with antineoplastics? J Oncol Pharm Pract. 2014;20(6):445-60. DOI:10.1177/1078155213514469

Casiraghi A, Franzè S, Rocco P, Minghetti P. Risk management of in- hospital administration of anticancer drugs: impact of Raccomandazione 14 from the Italian Ministry of Health. Tumori. 2016;102(Suppl. 1):2-6. DOI:10.5301/tj.5000538

Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol. 2010;6(3):220-37. DOI:10.1111/j.1743-7563.2010.01321.x

Leung M, Bland R, Baldassarre F, Green E, Kaizer L, Hertz S, et al. Safe Administration of Systemic Cancer Therapy: Introduction and General Methods 2012 [cited 2018 April 11]. Available at: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full /pebc12-12f.pdf.

Leung M, Bland R, Baldassarre F, Green E, Kaizer L, Hertz S, et al. Safe Administration of Systemic Cancer Therapy. Part 1: Safety During Chemotherapy Ordering, Transcribing, Dispensing, and Patient Identification 2012 [cited 2018 April 11]. Available at: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/su mmary/pebc12-12-1s.pdf.

Leung M, Bland R, Baldassarre F, Green E, Kaizer L, Hertz S, et al. Safe Administration of Systemic Cancer Therapy. Part 2: Administration of Chemotherapy and Management of Preventable Adverse Events 2014 [cited 2018 April 11]. Available at: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/summary/pebc12-12-2s.pdf.

Scottish Government. Guidance for the safe delivery of systemic anti- cancer therapy 2012 [cited 2018 April 11]. Available at: http://www.sehd.scot.nhs.uk/mels/CEL2012_30.pdf.

Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvet BE, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. Oncol Nurs Forum. 2017;44(1):31-43. DOI:10.1188/17.ONF.31-43

Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract. 2013;9(2 Suppl):5s-13s. DOI:10.1200/JOP.2013.000874

Jacobson JO, Polovich M, McNiff KK, LeFebvre KB, Cummings C, Galioto M, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum. 2009;36(6):651-8. DOI:10.1188/09.ONF.651-658

Goldspiel B, Hoffman JM, Griffith NL, Goodin S, DeChristoforo R, Montello CM, et al. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. Am J Health Syst Pharm. 2015;72(8):e6- e35. DOI:10.2146/sp150001

Greenall J, Shastay A, Vaida AJ, U D, Johnson PE, O’Leary J, et al. Establishing an international baseline for medication safety in oncology: Findings from the 2012 ISMP International Medication Safety Self Assessment(R) for Oncology. J Oncol Pharm Pract. 2015;21(1):26-35. DOI:10.1177/1078155214556522

ISMP Canada. ISMP International Medication Safety Self Assessment for Oncology 2012 [cited 2018 April 11]. Available at: https://mssa.ismp-canada.org/data/oncology/mssa_oncology.pdf.

Gilmore TR, Schulmeister L, Jacobson JO. Quality Oncology Practice Initiative Certification Program: Measuring implementation of chemotherapy administration safety standards in the outpatient oncology setting. J Oncol Pract. 2013;9(2 Suppl):14s-8s. DOI:10.1200/JOP.2013.000886

Griffin MC, Gilbert RE, Broadfield LH, Easty AE, Trbovich PL, Griffin MC, et al. ReCAP: Comparison of independent error checks for oral versus intravenous chemotherapy. J Oncol Pract. 2016;12(2):168-9; e80-7. DOI:10.1200/JOP.2015.005892

Ribed A, Escudero-Vilaplana V, Romero-Jiménez RM, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo-Séez M. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opin Drug Saf. 2016;15(4):427-35. DOI:10.1517/14740338.2016.1150998

Lester J. Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. Clin J Oncol Nurs. 2012;16(6):E192-7. DOI:10.1188/12.CJON.E192-E197

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: Recommendations from an international pharmacy panel. J Oncol Pract. 2011;7(1):7-12. DOI:10.1200/JOP.2011.7.1.e7

Rudnitzki T, McMahon D. Oral agents for cancer: safety challenges and recommendations. Clin J Oncol Nurs. 2015;19(3 Suppl):41-6. DOI:10.1188/15.S1.CJON.41-46

Grupo de Farmacia Oncológica de la SEFH. Plan estratégico de atención farmacéutica al paciente oncohematológico 2016 [cited 2018 April 11]. Available at: http://gruposdetrabajo.sefh.es/gedefo/images/stories/documentos/2016/plan%20estratgico%202020.pdf.

Arcusa Lanza A, León Carbonero AI, Vera García R, Juan Vidal OJ, Del Barco Berrón S, Guillot Morales M, et al. Hospitales de día en Oncología. Jara Sánchez C, Ayala de la Peña F, Virizuela JA, editors: Sociedad Española de Oncología Médica; 2015.

Jara C, Ayala F, Virizuela JA, Oncology Day Hospital Task Force. The oncology day hospital in Spain: An updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward. Clin Transl Oncol. 2017;19(3):269-72. DOI:10.1007/s12094-016-1610-1

Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, et al. Revisions to the 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards: Expanding the scope to include inpatient settings. J Oncol Pract. 2012;8(1):2-6. DOI:10.1200/JOP.2011.000339

North Wales Cancer Network. Standards for the safe use of oral anticancer medicines 2008 [cited 2018 April 11]. Available at: http://www.wales.nhs.uk/sites3/docopen.cfm?orgid=456&id=99534.

DOI: http://dx.doi.org/10.7399%2Ffh.11132